Holen Sie sich die Stockscreener-App
36.44
0.77%
0.28
Vorhandelsmarkt:
36.20
-0.24
-0.66%
Schlusskurs vom Vortag:
$36.16
Offen:
$36.05
24-Stunden-Volumen:
1.24M
Relative Volume:
0.53
Marktkapitalisierung:
$3.53B
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-383.17M
KGV:
-7.7453
EPS:
-4.7048
Netto-Cashflow:
$-307.84M
1W Leistung:
-3.01%
1M Leistung:
-37.87%
6M Leistung:
-37.60%
1J Leistung:
-8.07%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$35.06
$37.79
52-Wochen-Spanne:
$35.06
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
36.44 | 3.53B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-06 | Fortgesetzt | Guggenheim | Buy |
| 2026-09-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD - Investing.com
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD By Investing.com - Investing.com Canada
XENE Assumed by Guggenheim -- Buy Rating Assigned with Price Tar - GuruFocus
Xenon Pharmaceuticals stock gets 28,350 awards for new hires - AD HOC NEWS
President of Xenon Pharmaceuticals Picks Up 88% More Stock - Simply Wall Street
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Eight new Xenon employees get options to buy shares at $38.93 - Stock Titan
Xenon Pharmaceuticals (XENE) Shares Rise After CEO and CFO Buy $1.7M in Stock - GuruFocus
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase - GuruFocus
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says - Yahoo Finance
Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing - Yahoo Finance
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares. - Stock Titan
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock. - Stock Titan
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing - AD HOC NEWS
Total common shares outstanding of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals Inc. Balance Sheet – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance Australia
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Yahoo Finance
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - PR Newswire
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - GlobeNewswire
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment - Yahoo Finance
Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data - Yahoo Finance
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - benzinga.com
Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold From Buy, Adjusts PT to $46 From $90 - Yahoo Finance
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Yahoo Finance
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause - Yahoo Finance
Wedbush Cuts Price Target on Xenon Pharmaceuticals to $55 From $71, Keeps Outperform Rating - Yahoo Finance
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. - Barron's
Xenon Announces Azetukalner NDA Submission to FDA for Focal - GlobeNewswire
Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here - Seeking Alpha
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care - Yahoo Finance
A drugmaker plans a 30-minute healthcare talk in Boston Sept. 9. Xenon will present. - Stock Titan
Xenon to Present at Wells Fargo Healthcare Conference - Yahoo Finance
Behavioral Patterns of XENE and Institutional Flows - Stock Traders Daily
Xenon Pharmaceuticals stock holds firm as analysts stick to buy ratings - ad-hoc-news.de
Xenon Pharmaceuticals (XENE) CMO sells 7,068 shares in Rule 10b5-1 plan trades around $61. - Stock Titan
Xenon Pharma (NASDAQ: XENE) holder to sell 7,068 shares - Stock Titan
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders - Yahoo Finance
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Sep 30 '26 |
Buy |
37.38 |
30,000 |
1,121,400 |
49,923 |
| Svoronos Dawn | Director |
Sep 01 '26 |
Option Exercise |
8.15 |
5,144 |
41,924 |
31,373 |
| CHRISTOPHER KENNEY | Officer |
Aug 28 '26 |
Proposed Sale |
61.93 |
7,068 |
437,721 |
0 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer |
Aug 28 '26 |
Sale |
60.25 |
7,068 |
425,829 |
2 |
| STEVEN GANNON | Director |
Aug 11 '26 |
Proposed Sale |
64.06 |
10,000 |
640,553 |
0 |
| GANNON STEVEN | Director |
Aug 11 '26 |
Sale |
64.06 |
10,000 |
640,550 |
1,870 |
| GARY PATOU | Director |
Jun 05 '26 |
Proposed Sale |
52.99 |
1,322 |
70,053 |
0 |
| PATOU GARY | Director |
Jun 05 '26 |
Sale |
53.14 |
1,322 |
70,251 |
24,896 |
| Cannon Gillian | Director |
Jun 05 '26 |
Sale |
53.14 |
1,190 |
63,237 |
1,455 |
| GILLIAN CANNON | Director |
Jun 05 '26 |
Proposed Sale |
52.99 |
1,190 |
63,058 |
0 |
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):